Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus
| Autor: | Zulfiye Gul, Sinan Cavun, Metin Guclu, Sinem Kiyici |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism exenatide 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Gastroenterology lcsh:Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences 0302 clinical medicine Endocrinology Weight loss Diabetes mellitus Internal medicine Orexigenic Internal Medicine medicine Glycemic lcsh:RC648-665 diabetes business.industry Research Type 2 Diabetes Mellitus Anthropometry medicine.disease Metformin ghrelin Ghrelin medicine.symptom business Exenatide medicine.drug |
| Zdroj: | Endocrine Connections, Vol 7, Iss 1, Pp 193-198 (2018) Endocrine Connections |
| ISSN: | 2049-3614 |
| Popis: | Aim In the present study, we investigated the long-term effects of exenatide treatment on serum fasting ghrelin levels in patients with type 2 diabetes mellitus. Methods Type 2 diabetic patients, who were using metformin with and without the other antihyperglycemic drugs on a stable dose for at least 3 months, were enrolled in the study. BMI>35 kg/m2 and HbA1c>7.0% were the additional inclusion criteria. Oral antihyperglycemic drugs, other than metformin, were stopped, and metformin treatment was continued at 2000 mg per day. Exenatide treatment was initiated at 5 µg per dose subcutaneously (sc) twice daily, and after one month, the dose of exenatide was increased to 10 µg twice daily. Changes in anthropometric variables, glycemic control, lipid parameters and total ghrelin levels were evaluated at baseline and following 12 weeks of treatment. Results Thirty-eight patients (male/female = 7/31) entered the study. The mean age of patients was 50.5 ± 8.8 years with a mean diabetes duration of 8.5 ± 4.9 years. The mean BMI was 41.6 ± 6.3 kg/m2 and the mean HbA1c of patients was 8.9 ± 1.4%. The mean change in the weight of patients was −5.6 kg and the percentage change in weight was −5.2 ± 3.7% following 12 weeks of treatment. BMI, fasting plasma glucose and HbA1c levels of patients were decreased significantly (P P P = 0.024). Conclusion These results suggest that the effects of exenatide on weight loss may be related with the suppression of serum fasting ghrelin levels, which is an orexigenic peptide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|